Phase 1 Advanced Breast Cancer Clinical Trials
24 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 24 trials
Recruiting
Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer
Bristol-Myers Squibb234 enrolled21 locationsNCT06997029
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)
Pfizer260 enrolled9 locationsNCT07318805
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled39 locationsNCT06827236
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer
Boundless Bio, Inc.96 enrolled8 locationsNCT07408089
Recruiting
Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled32 locationsNCT06638307
Recruiting
Phase 1Phase 2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1Phase 2
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled10 locationsNCT06993844
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 1
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast
Calibr, a division of Scripps Research20 enrolled5 locationsNCT06878248
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 1Phase 2
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd.196 enrolled1 locationNCT07002177
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
Study of DM5167 in Patients With Advanced Solid Tumors
Advanced Breast Cancer
DIGMBIO58 enrolled4 locationsNCT07101601
Recruiting
Phase 1
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Advanced Breast CancerAdvanced Prostate CancerTNBC+3 more
Jiangsu Hansoh Pharmaceutical Co., Ltd.157 enrolled1 locationNCT06769425
Recruiting
Phase 1
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.32 enrolled2 locationsNCT06710990
Recruiting
Phase 1
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Advanced Breast Cancer
Shenzhen Celconta Life Science Co., Ltd.18 enrolled1 locationNCT06724835
Recruiting
Phase 1Phase 2
A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
HER-2 Positive Advanced Breast Cancer
Zunyi Medical College67 enrolled1 locationNCT06470347